ProCE Banner Activity

CARDINAL: Phase III Study of Sutimlimab in Patients With Cold Agglutinin Disease and a Recent History of Transfusion

Slideset Download
Conference Coverage
First-in-class inhibitor of classical complement pathway demonstrates rapid and durable efficacy in cold agglutinin disease.

Released: December 15, 2019

Expiration: December 13, 2020

No longer available for credit.

Share

Provided by

Jointly provided by the Annenberg Center for Health Sciences at Eisenhower and Clinical Care Options, LLC
ProCE Banner

Supporters

Supported by educational grants from

AstraZeneca

Celgene

Dova Pharmaceuticals

Janssen Biotech, Inc., administered by Janssen Scientific Affairs, LLC

Karyopharm Therapeutics

Loxo Oncology subsidiary of Eli Lilly

Pharmacyclics an AbbVie Company